{"id":"NCT01214239","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug na√Øve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control","officialTitle":"A Randomized, db, Placebo Controlled Parallel Group Efficacy and Safety Study Over 24 Weeks in T2D Patients in China","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-05","completion":null,"firstPosted":"2010-10-05","resultsPosted":"2013-07-19","lastUpdate":"2016-08-25"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Linagliptin","otherNames":[]}],"arms":[{"label":"Linagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with type 2 diabetes and insufficient glycaemic control.","primaryOutcome":{"measure":"HbA1c Change From Baseline at Week 24","timeFrame":"Baseline and at week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.18,"sd":0.1},{"arm":"Linagliptin 5mg","deltaMin":-0.68,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["China","Malaysia","Philippines"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":99},"commonTop":["Hyperlipidaemia","Hyperglycaemia"]}}